Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Study-specific guidelines for monitoring, evaluating, and managing ILD/pneumonitis in T-DXd clinical trials, including dose modification and supportive care recommendations, were updated in 2019 (Table 1) with more specific details regarding dosages and duration of steroid treatment, including for grade 1 events, than previous guidelines. , , The approved labels for T-DXd also include warnings regarding ILD/pneumonitis and guidelines for its management.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
